
    
      Primary:

      â€¢ To evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day
      titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo

      Key Secondary:

        -  To evaluate the effect of seladelpar on normalization of alkaline phosphatase (AP)
           levels

        -  To evaluate the effect of seladelpar on pruritus
    
  